French Innovator Torskal Teams Up with SaniMed to Drive Global Non-Invasive Cancer Therapy Revolution

Torskal S.A.S., a French oncology innovation company developing groundbreaking non-ionizing plasmonic photothermal therapy (PTT) for skin cancers and other solid tumors, is pleased to announce its partnership with SaniMed Science Group, a U.S.-based healthcare advisory firm headquartered in the Texas Medical Center, Houston.

---

Under a formal Financial Advisory and Business Consulting Agreement signed in March 2025, SaniMed will act as Torskal’s fundraising and strategic business consultant for investor engagement across the United States and selected international markets. With extensive experience in cross-border life science investments, clinical research collaborations, and U.S. regulatory pathways, SaniMed brings a strong network of sophisticated investors, particularly from Asia, as well as commercialization expertise tailored for innovative medical technologies.

---

The scope of this collaboration includes:

• Fundraising support for Torskal’s equity financing rounds (with specific structures for investors from USA and beyond);

• Business strategy consultation, including go-to-market planning, KOL engagement, and partnership development;

• Representation at international investor meetings and roadshows;

• Investor due diligence facilitation and coordination.

---

This strategic partnership enhances Torskal’s global reach and enables the company to expand its footprint into the U.S. and Asian markets while advancing the clinical and commercial development of its TSK-001 PTT platform. Together, Torskal and SaniMed are committed to bringing next-generation, non-invasive cancer therapies to patients worldwide through science, collaboration, and investment.